dr camidge on novel nsclc agents: we want to see the duration of benefit
Published 5 years ago • 111 plays • Length 0:43Download video MP4
Download video MP3
Similar videos
-
1:52
dr. camidge on optimal therapy in egfr nsclc
-
1:00
dr. camidge on phase i study with azd9291 in nsclc
-
56:39
the ros1ders interview dr ross camidge 16 may 2019
-
1:51
dr. camidge on biomarker combinations in nsclc
-
0:30
copy of dr. camidge on the keynote-024 trial in nsclc
-
9:36
dr. d ross camidge on teliso-v monotherapy in patients with previously treated c-met advanced nsclc
-
1:58
dr. camidge on mechanisms of resistance to tkis in nsclc
-
1:27
dr. camidge on the keynote-024 trial in nsclc
-
47:57
lung cancer new treatment 2023
-
1:04:55
treatment of unresectable stage 3 non-small cell lung cancer
-
56:23
small cell lung cancer treatment landscape: hope is on the horizon - 03/19/24 - living room series
-
1:37
dr. camidge on the alex trial in patients with alk nsclc
-
1:51
dr. camidge discusses treatment of patients with alk nsclc
-
1:55
dr. d. ross camidge on targeted therapies in adjuvant non-small cell lung cancer
-
0:47
combining radiotherapy with novel agents in nsclc
-
1:40:14
at the crossroads of evidence-based nsclc care
-
1:35
d. ross camidge discusses the development of a new lung cancer drug
-
6:46
dr. camidge discusses launch of phase 2 trial evaluating raf/mek inhibitor in nsclc
-
47:52
introducing novel immunotherapeutic approaches for metastatic nsclc without driver mutations
-
3:24
novel immunotherapy agents on the horizon for lung cancer
-
3:26
the impact of novel nsclc immunotherapies
-
2:29
dr. ross camidge discusses crizotinib in ros1 rearranged nsclc